A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

Overview

Información sobre este estudio

Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Age range: 18-60 years old (inclusive).
  • BMI ≤ 40 kg/m^2.
  • Not a current smoker or tobacco user.
  • Gender: Both males and females will be allowed to participate in the study.
  • Target disease or condition: Healthy and OSA subjects.
  • Absence of any chronic medical conditions other than seasonal or environmental allergies, depression, acid reflux and acne.
  • Individuals with untreated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study.
  • On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Ceterizine, Fexofenadine, Desloratadine, Loratadine, etc., depression, acid reflux (such as antacids or PPIs), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
  • Not pregnant or breast feeding and not intending to become pregnant or breast feed.
  • Ability to provide written informed consent.
  • If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.

Exclusion Criteria:

  • Vulnerable study population will be excluded.
  • Presence of chronic kidney disease (creatinine > 2.5 mg/dL) and/or active cancer.
  • Pregnancy.
  • Anemic (hemoglobin < 12.0 g/dL for men and < 11.0 g/dL for women).
  • Smoking.
  • Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors).
  • Blood or plasma donation during the past 2 months.

 

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Virend Somers, M.D., Ph.D.

Abierto para la inscripción

Contact information:

CPL OSA Sleep Study

CPLOSA@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20338057

Mayo Clinic Footer